4.4 Article

Prognostic Value of Modeled PSA Clearance on Biochemical Relapse Free Survival After Radical Prostatectomy

Journal

PROSTATE
Volume 69, Issue 12, Pages 1325-1333

Publisher

WILEY-LISS
DOI: 10.1002/pros.20978

Keywords

biomarker; metabolite clearance rate; prostate specific antigen; prostate cancer; prostatectomy; prognosis

Funding

  1. INSERM, France

Ask authors/readers for more resources

PURPOSES. Using population kinetic approach, we modeled PSA decline equations in patients with prostate cancer after radical prostatectomy (RP). We looked for relationships between early PSA decrease profile, characterized by PSA clearance (CL(PSA)) or half-life (H I-PIA and the 2-year biochemical relapse free survival (bRFS). PATIENTS AND METHODS. We performed a retrospective Study oil 55 patients treated with RP and with at least 2 PSA measurements in the post-operative month. A population kinetic model was investigated with NONMEM (R). The prognostic factors regarding bRFS were assessed using univariate and multivariate analyses. RESULTS. The best model describing the PSA post-operative decrease was bi-compartmental and fit patient data well. Median CL(PSA) was 0.034 (terciles were 0.023 and 0.048). The significant prognostic factors associated with a better bRFS With Univariate analysis were lower CL(PSA) terciles (2-year bRFS = 100% vs. 85.1% vs. 66.7% if CL(PSA) < 0.023, 0.023 <= CL(PSA) < 0.048 or CL(PSA) >= 0.0480, P = 0.006) as well as initial PSA < 7 ng/ml, pT2 stage (vs. pT3), pN0 (vs. pN1) and low main Gleason score (3/5 vs. 4/5). Among these factors, CL(PSA) was the only independent prognostic factor with multivariate analysis regarding bRFS (HR=0.92, 95%CI = [0.86-0.981, P = 0.0088). CONCLUSION. CLPSA determined with 4 PSA concentrations in the first month following the RP may predict the biochemical relapse risk of prostate cancer patients, thus enabling early identification of high-risk patients requiring adjuvant treatment. A prospective validation of these results is required. Prostate 69: 1325-1333, 2009. (C) 2009 Wiley-Liss, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

Emilie Henin, Martin Bergstrand, Joseph F. Standing, Mats O. Karlsson

AAPS JOURNAL (2012)

Review Oncology

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment

R. Almufti, M. Wilbaux, A. Oza, E. Henin, G. Freyer, M. Tod, O. Colomban, B. You

ANNALS OF ONCOLOGY (2014)

Article Oncology

Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements

B. You, R. Harvey, E. Henin, H. Mitchell, F. Golfier, P. M. Savage, M. Tod, M. Wilbaux, G. Freyer, M. J. Seckl

BRITISH JOURNAL OF CANCER (2013)

Article Oncology

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients

M. Wilbaux, E. Henin, A. Oza, O. Colomban, E. Pujade-Lauraine, G. Freyer, M. Tod, B. You

BRITISH JOURNAL OF CANCER (2014)

Article Pharmacology & Pharmacy

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma

David Ternant, Guillaume Cartron, Emilie Henin, Michel Tod, Pascal Girard, Gilles Paintaud

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)

Article Pharmacology & Pharmacy

Solid oral forms availability in children: a cost saving investigation

Audrey Lajoinie, Emilie Henin, Behrouz Kassai, David Terry

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)

Article Oncology

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation

Ines Paule, Michel Tod, Emilie Henin, Benoit You, Gilles Freyer, Pascal Girard

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)

Article Oncology

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS)

Emilie Henin, Benoit Blanchet, Pascaline Boudou-Rouquette, Audrey Thomas-Schoemann, Gilles Freyer, Michel Vidal, Francois Goldwasser, Michel Tod

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)

Article Pharmacology & Pharmacy

Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure

Anne-Charlotte Castellan, Michel Tod, Francois Gueyffier, Melanie Audars, Frederic Cambriels, Behrouz Kassai, Patrice Nony

CLINICAL PHARMACOKINETICS (2013)

Article Oncology

Predictors of prescription errors involving anticancer chemotherapy agents

Florence Ranchon, Celine Moch, Benoit You, Gilles Salles, Verane Schwiertz, Nicolas Vantard, Emilie Franchon, Claude Dussart, Emilie Henin, Olivier Colomban, Pascal Girard, Gilles Freyer, Catherine Rioufol

EUROPEAN JOURNAL OF CANCER (2012)

Article Biochemistry & Molecular Biology

Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein

Lorena Martinez, Ophelie Arnaud, Emilie Henin, Houchao Tao, Vincent Chaptal, Rupak Doshi, Thibault Andrieu, Sebastien Dussurgey, Michel Tod, Attilio Di Pietro, Qinghai Zhang, Geoffrey Chang, Pierre Falson

FEBS JOURNAL (2014)

Article Oncology

Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development

Melanie Wilbaux, Emilie Henin, Amit Oza, Olivier Colomban, Eric Pujade-Lauraine, Gilles Freyer, Michel Tod, Benoit You

GYNECOLOGIC ONCOLOGY (2014)

Article Pharmacology & Pharmacy

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Steve Choy, Emilie Henin, Jan-Stefan van der Walt, Maria C. Kjellsson, Mats O. Karlsson

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)

Article Oncology

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO

Alexandre Sostelly, Emilie Henin, Laure Chauvenet, Anne-Claire Hardy-Bessard, Veronique Jestin-Le Tallec, Sylvie Kirsher, Cecile Leyronnas, Catherine Ligeza-Poisson, Soraya Ramdane, Jacques Salavt, Sylvie Van-Hult, Jean-Michel Vannetzel, Gilles Freyer, Michel Tod, Claire Falandry

JOURNAL OF GERIATRIC ONCOLOGY (2013)

Review Biotechnology & Applied Microbiology

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

Salima Hamizi, Gilles Freyer, Naoual Bakrin, Emilie Henin, Amina Mohtaram, Olivia Le Saux, Claire Falandry

ONCOTARGETS AND THERAPY (2013)

No Data Available